5'-STRUCTURAL Analysis of Genes Encoding Polymorphic Antigens of Chemically Induced Tumors (original) (raw)
Related papers
Tumor rejection antigens of chemically induced sarcomas of inbred mice
Proceedings of the …
Chemically induced sarcomas of inbred mice are immunogenic in syngeneic hosts, and preimmunization with tumor cells leads to resistance to subsequent tumor transplants. The tumor rejection antigens (TRAs) that mediate this reaction are highly specific for each tumor; cross-protection between different syngeneic sarcomas is rare. Isolated membrane and cytosol fractions from two antigenically distinct BALB/c sarcomas, Meth A and CMS5, have TRA activity, and biochemical characterization of the active components from the cytosol and plasma membranes of these two tumors identified a glycoprotein ofMr 96,000. Immunization with unfractionated Meth A cytosol frequently leads to tumor enhancement, but the tumor-enhancing activity (TEA) is lost on fractionation and
Identification of a human homologue of the murine tumor rejection antigen GP96
Cancer research, 1989
A family of cell surface glycoproteins with a molecular weight of 96,000 (gp96) has recently been implicated in the individually distinct immunogenicity of chemically induced sarcomas of inbred mice. Rabbit antiserum to murine gp96 detects an antigenically related Mr 96,000 cell surface glycoprotein on two cultured human melanoma cell lines, SK-MEL-13 and SK-MEL-177. Molecular probes for 5' and 3' ends of the murine gp96 gene detect a 3.5-kilobase transcript in RNA preparations from melanoma cells, similar to the murine gp96 transcript. While 5' probes do not hybridize to Southern blots of genomic human DNA, the 3' probes identify several distinct bands under stringent hybridization and washing conditions. This suggests that the 3' end of the gp96 gene is more conserved than its 5' end. No gross alterations in gp96 gene organization were detected in melanoma cells. B-lymphoblastoid cell lines derived from four different individuals also showed no restriction ...
Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas
Cancer research, 1987
A tumor-specific antigen (TSA) expressed on the chemically induced BALB/c Meth A sarcoma and one of 22 other BALB/c sarcomas tested, CMS13, was detected in in vitro cellular and humoral assays. The distribution pattern of the TSA defined in a complement-dependent microcytoxicity assay by cytotoxic antibodies present in CMS13 antisera was similar to that detected by a cytotoxic T-cell clone, designated CTLL-MA10B, in an 18-h cell-mediated cytotoxicity assay. The serologically defined TSA was shown to be expressed on gp96, a Mr 96,000 glycoprotein isolated from Meth A cytosol with immunoprotective activity in in vivo tumor rejection assays. Immunization of BALB/c mice with Meth A, CMS13, or preparations of gp96 isolated from these sarcomas induced tumor resistance in these mice to Meth A and CMS13 but not CMS5, an antigenically unrelated sarcoma. These results suggest that the shared TSA is expressed on gp96 and is functional in tumor rejection assays.
Purification and analysis of a human sarcoma associated antigen
Cancer Letters, 1993
S,, a heterophile antigen present on human sarcoma cell lines in culture, has been previously defined by this laboratory . This antigen is also present in guinea-pig kidney. Purification of the antigen to homogeneity has now been achieved by a combination of ammonium sulfate fractionation, DEAE-cellulose, sephadex, high pressure liquid chromatography and affinity chromotography. S, is a monomeric protein of 70 000 Da, as indicated by the presence of a single band on SDS-PAGE. Amino acid analysis demonstrates the prevalence of glycine, lysine and glutamic acid. Aspartic acid was found to be the N-terminal residue with further sequence of glycine-valinealanine-glutamic acid (gly-val-ala-glut).
Cancer Research
A tumor-specific antigen (TSA) expressed on the chemically induced BALB/c Meth A sarcoma and one of 22 other BALB/c sarcomas tested, CMS13, was detected in in vitro cellular and humoral assays. The distribution pattern of the TSA defined in a complement-dependent microcytoxicity assay by cytotoxic antibodies present in CMS13 antisera was similar to that detected by a cytotoxic T-cell clone, designated ('III MA10B, in an 18-h cell-mediated cytotoxicity assay. The serologically defined TSA was shown to be expressed on gp%, a \t, 96,000 glycoprotein isolated from Meth A cytosol with immunoprotective activity in in r/ro tumor rejection assays. Immunization of BALB/c mice with Meth A, (MM1, or preparationsof gp% isolated from these sarcomas induced rumor resistance in these mice to Meth A and CMS13 but not CMS5, an antigenically unrelatedsarcoma. These results suggest that the shared TSA is expressed on gp% and is functional in rumorrejection assays.
Journal of Experimental Medicine, 1977
As background for a serological definition of the unique antigens of chemically induced sarcomas, we have typed a series of fibroblast and sarcoma cell lines of BALB/c and C57BL/6 origin by cytoxicity and absorption tests for murine leukemia virus (MuLV)-related cell surface antigens and known alloantigens. 7 of the 17 cultured lines expressed the range of cell surface antigens associated with MuLV (GIX, GCSA, gp70, p30), and this was invariably associated with MuLV production. In nonproducer lines of C57BL/6 (but not BALB/c) origin, a MuLV-gp70-like molecule was found on the surface of fibroblasts and sarcoma cells. The alloantigenic phenotype of these MuLV+ and MuLV- cell lines was H-2D+, H-2K+, Thy-1.2+ or -, PC.1+ or -, Lyt-1.2-, Lyt-2.2-, Ia.7-, and TL.2-. A unique antigen was defined on the BALB/c ascites sarcoma Meth A with antisera prepared in BALB/c or (BALB/c X C57BL/6)F1 mice. Tissue culture lines derived from this tumor were MuLV-, which facilitated serological study of ...
Cancer Research
Fusion products of spleen cells of W/FuDp rats immunized with a methylcholanthrene-induced BALB/c sarcoma, CA-2, and mouse myeloma cells were screened in an attempt to identify a monoclonal antibody defining the individually distinct tumor-spe cific transplantation antigen of CA-2. A hybridoma, MP/69/04, was isolated which produces an lgG2a monoclonal antibody that recognized a tumor-restricted antigen of CA-2. In direct binding assay, MP/69/04 reacted only with 2 of 15 methylcholanthrene induced BALB/c sarcomas tested. Thymus, spleen, lymph nodes, bone marrow, brain, adult lung fibroblasts, newborn muscle fibroblasts and 3T3 cells were negative. Absorption tests revealed, however, expression of the MP/69/04 determinant on 8 of the 12 murine leukemia virus (MuLV) producer BALB/c sarcoma tested. The antigen was not detected on any of the three non-producer sarcomas tested nor on a wide range of normal tissues and cell lines. An N-dualtropic MuLV was isolated from CA-2, and cell lines susceptible to infection by this virus were shown to express the MP/69/04 epitope. By Western blotting, the MP/69/04 epitope was identified as being expressed on the MuLV structural protein with a molecular weight of 12,000, present in CA-2 cells and in the purified CA-2 MuLV. These results indicate the MP/69/04 antigen is not a unique tumorspecific transplantation antigen but is a gag product of a recom binant retrovirus which is expressed on the cell surface of many MuLV + methylcholanthrene-induced BALB/c fibrosarcomas.
Proceedings of the National Academy of Sciences, 1985
Cancers induced by physical or chemical carcinogens express tumor-specific antigens that are uniquely specific for any given tumor; therefore, there is a seemingly endless variety of these unique antigens. We have studied a UV-induced fibrosarcoma, designated 1591, to elucidate the obscure molecular nature and genetic origins of unique tumor-specific antigens. A monoclonal antibody raised against syngeneic 1591 tumor cells has unique tumor specificity. This tumor-specific monoclonal antibody precipitated from the tumor a 45-kDa molecule associated with a 12-kDa molecule having the pI of beta2-microglobulin. This and other evidence indicated that the 1591 tumor expresses a novel class I molecule. A 1591 variant selected for the absence of binding to the monoclonal antibody lacked the novel class I MHC molecule as well as reactivity with cytotoxic T lymphocytes specific for the 1591 tumor. Furthermore, tumor cells bearing the antigen are rejected while variants that have lost the anti...